光大证券指出,业绩持续超预期。海外布局继续推进,DreamCIS有望韩国上市。科创板+港股松绑,助力新药投资业务。作为国内临床CRO龙头,充分受益国内创新大潮。暂时维持19-21年EPS预测为0.92/1.23/1.62元,分别同比增长46%/34%/31%,对应19-21年PE为68/51/39倍,维持“买入”评级。
“特别声明:以上作品内容(包括在内的视频、图片或音频)为凤凰网旗下自媒体平台“大风号”用户上传并发布,本平台仅提供信息存储空间服务。
Notice: The content above (including the videos, pictures and audios if any) is uploaded and posted by the user of Dafeng Hao, which is a social media platform and merely provides information storage space services.”